Skip to content

The efficacy of gabapentin on tinnitus

Comparison of the efficacy of gabapentin with placebo on Idiopathic tinnitus

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200127046283N1
Enrollment
56
Registered
2020-06-10
Start date
2020-06-22
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic tinnitus. Tinnitus

Interventions

Intervention 1: Intervention group: The treated individuals included all patients with idiopathic tinnitus referred to the ETN Clinic of Al-Zahra Hospital in 1998-99, for 12 weeks after the interventi

Sponsors

Zahedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: All the patient with idiopathic tinnitus referred to the ENT clinic of the Al-Zahra hospital Age between 18 and 65 Satisfaction to enter this study Patient assistance to use the drug No pregnancy , lactescent, or plan to pregnancy in the next 6 months Normal audiometry test

Exclusion criteria

Exclusion criteria: Use narcotic or alcohol or sedative drugs in the past 48 hours Use MAOI, SSRI, TCA ,phenothiazine, soporific drugs in the past Sensitivity to gabapentine No satisfaction with being a case study in this study No assistance to use the drug Patient with pulsative tinnitus Patient with acute / choronic internal or middle ear infection Patient with thyroid disease Patient with rheumatologic disease Deals with noisy workplace Age more than 65 years Simultaneous use of other drugs except for gabapentin

Design outcomes

Primary

MeasureTime frame
The score of tinnitus in tinnitus severity index questionnaire and visual analogue scale. Timepoint: The amount of tinnitus at the beginning of the study and 1, 2 and 3 months after starting the drug and placebo will be measured. Method of measurement: Tinnitus severity index questionnaire, visual analogue scale and 5 point scale for satisfaction.

Secondary

MeasureTime frame
Side effects of prescribed drug. Timepoint: 1-2-3 months after using drug. Method of measurement: ask about vertigo? nasea? drowsiness? biurred vision ?fatigue.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Rashidi ravari

Zahedan University of Medical Sciences

rashidi.sd@gmail.com+98 54 3321 4157

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026